{{Rsnum
|rsid=3129900
|Gene=C6orf10
|Chromosome=6
|position=32338202
|Orientation=plus
|GMAF=0.1428
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=C6orf10
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 5.3 | 28.3 | 66.4
| HCB | 1.5 | 10.3 | 88.2
| JPT | 0.0 | 0.9 | 99.1
| YRI | 6.1 | 37.4 | 56.5
| ASW | 3.5 | 28.1 | 68.4
| CHB | 1.5 | 10.3 | 88.2
| CHD | 1.8 | 22.0 | 76.1
| GIH | 1.0 | 10.9 | 88.1
| LWK | 0.9 | 38.2 | 60.9
| MEX | 5.2 | 20.7 | 74.1
| MKK | 5.8 | 37.8 | 56.4
| TSI | 0.0 | 22.5 | 77.5
| HapMapRevision=28
}}{{PMID Auto
|PMID=20639878
|Title=A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
}}

People with one or two copies of the G allele at this SNP are 3.5 times more likely to suffer liver injury than TT carriers when taking the prescription [[nonsteroidal anti-inflammatory drug]] ([[NSAID]]) lumiracoxib. This new pain medication was approved in Europe in late 2006, but  because of a higher incidence of liver injury and patient deaths than among patients using other NSAIDs, it was withdrawn from the market in most countries. It is still sold in some countries under the brand names Prexige and Joicela.

{{PMID Auto
|PMID=17660530
|Title=Risk alleles for multiple sclerosis identified by a genomewide study.
}}

{{PMID Auto
|PMID=20546594
|Title=An application of Random Forests to a genome-wide association dataset: methodological considerations & new findings.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}